How big is Synopsys, Inc.?

As of Jun 18, Synopsys, Inc. has a market capitalization of $75.76 billion, with recent net sales of $6.21 billion and a net profit of $1.33 billion over the last four quarters.

Market Cap: As of Jun 18, Synopsys, Inc. has a market capitalization of 75,759.24 million, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Synopsys, Inc. reported net sales of 6,213.66 million and a net profit of 1,329.93 million.<BR><BR>Balance Sheet Snapshot: As of Oct 24, the company reported shareholder's funds of 8,990.70 million and total assets of 13,073.56 million.

What does Synopsys, Inc. do?

Synopsys, Inc. specializes in electronic design automation (EDA) software, intellectual property, and services for integrated circuits. As of April 2025, it reported net sales of $1.6 billion and a market cap of approximately $75.8 billion.

Overview:<BR>Synopsys, Inc. provides software, intellectual property (IP), and services within the software products industry, focusing on electronic design automation (EDA) for integrated circuits.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,603 Million (Quarterly Results - Apr 2025) <BR>Most recent Net Profit: 349 Million (Quarterly Results - Apr 2025) <BR>Market-cap: USD 75,759.24 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 56.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.41 <BR>Return on Equity: 13.98% <BR>Price to Book: 7.64<BR><BR>Contact Details:<BR>Address: 690 E Middlefield Rd, MOUNTAIN VIEW CA: 94043-4010 <BR>Tel: ['1 650 5845000', '1 650 5841901'] <BR>Fax: 1 302 6365454 <BR>Website: https://www.synopsys.com/

Should I buy, sell or hold Synopsys, Inc.?

Who are in the management team of Synopsys, Inc.?

As of March 2022, Synopsys, Inc.'s management team includes Co-CEOs Dr. Aart de Geus and Dr. Chi-Foon Chan, along with Lead Independent Director Mr. Roy Vallee and several independent directors.

As of March 2022, the management team of Synopsys, Inc. includes:<BR><BR>- Dr. Aart de Geus, who serves as the Chairman of the Board and Co-Chief Executive Officer.<BR>- Dr. Chi-Foon Chan, who is the President, Co-Chief Executive Officer, and a Director.<BR>- Mr. Roy Vallee, who is the Lead Independent Director.<BR>- Ms. Jeannine Sargent, who is a Director.<BR>- Ms. Janice Chaffin, who is an Independent Director.<BR>- Mr. Bruce Chizen, who is also an Independent Director.<BR>- Ms. Mercedes Johnson, who serves as an Independent Director.<BR><BR>In summary, the key members of Synopsys, Inc.'s management team include Dr. Aart de Geus and Dr. Chi-Foon Chan as Co-CEOs, along with several independent directors and a lead independent director.

Is Synopsys, Inc. technically bullish or bearish?

As of October 3, 2025, Synopsys, Inc. shows a mildly bearish technical trend, with underperformance against the S&P 500 and bearish indicators from MACD and Bollinger Bands, despite a mildly bullish daily moving average.

As of 3 October 2025, the technical trend for Synopsys, Inc. has changed from sideways to mildly bearish. The weekly and monthly MACD indicators are both mildly bearish, and Bollinger Bands also indicate a bearish stance on both time frames. The daily moving averages show a mildly bullish signal, but this is overshadowed by the overall bearish indicators. The KST is mildly bearish for both weekly and monthly periods, while the Dow Theory shows no trend in either time frame. <BR><BR>In terms of performance, Synopsys has underperformed the S&P 500 across multiple periods, with a 1-month return of -20.05% compared to the S&P 500's 4.15%, and a 1-year return of -4.19% versus the S&P 500's 17.82%. Overall, the current technical stance is mildly bearish.

Is Synopsys, Inc. overvalued or undervalued?

As of November 7, 2025, Synopsys, Inc. is considered overvalued with a valuation grade of "expensive," reflected by high ratios like a P/E of 56 and underperformance against the S&P 500, showing a year-to-date return of -17.43% compared to the index's 14.40%.

As of 7 November 2025, the valuation grade for Synopsys, Inc. has moved from very expensive to expensive, indicating a slight improvement but still suggesting overvaluation. The company appears overvalued based on its high valuation ratios, including a P/E ratio of 56, an EV to EBITDA of 42.37, and a Price to Book Value of 7.81. In comparison to peers, Synopsys has a significantly higher P/E ratio than Microsoft Corp. at 36.17 and Oracle Corp. at 51.69, which further supports the notion of overvaluation.<BR><BR>Additionally, Synopsys has underperformed against the S&P 500 across multiple time frames, with a year-to-date return of -17.43% compared to the S&P 500's 14.40%, and a one-year return of -28.63% versus the S&P 500's 12.65%. This trend reinforces the assessment that the stock is currently overvalued in the market.